Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data-Reference-Cited by-同舟云学术

Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data

Published:2023-10 Issue:5 Volume:21 Page:517-529
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Swami Umang^ORCID,Aggarwal Himani^ORCID,Zhou Mo^ORCID,Jiang Shan,Kim Jeri,Li Weiyan,Laliberté François,Emond Bruno^ORCID,Agarwal Neeraj^ORCID

Funder

AstraZeneca

Merck Sharp and Dohme

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference23 articles.

1. Cancer statistics, 2022;Siegel;CA Cancer J Clin,2022

2. Current management of castrate-resistant prostate cancer;Hotte;Curr Oncol,2010

3. Characterising the castration-resistant prostate cancer population: a systematic review;Kirby;Int J Clin Pract,2011

4. Predicting time from metastasis to overall survival in castration-resistant prostate cancer: results from SEARCH;Moreira;Clin Genitourin Cancer,2017

5. United States Food and Drug Administration. RUBRACA® (rucaparib) – accelerated approval.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Talazoparib for the treatment of prostate cancer;Expert Opinion on Pharmacotherapy;2024-08-29

2. Treatment patterns for patients with BRCA1/2-positive metastatic castration-resistant prostate cancer;The Oncologist;2024-07-31

3. Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States;Journal of Managed Care & Specialty Pharmacy;2024-07

4. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes;Annals of Oncology;2024-05

5. Survival after docetaxel for metastatic castration-resistant prostate cancer in a rural health care setting;Współczesna Onkologia;2024